The efficacy of malaria chemoprofylaxis

dc.contributor.author	Σαρίδη, Μαρία	el
dc.contributor.author	Παππά, Βασιλική	el
dc.contributor.author	Σαρόγλου, Γιώργος	el
dc.date.accessioned	2014-07-18T20:35:30Z
dc.date.available	2014-07-18T20:35:30Z
dc.date.issued	2014-07-18
dc.identifier.uri	http://hdl.handle.net/11400/1394
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	www.hsj.gr	el
dc.subject	Primaquine
dc.subject	doxycycline
dc.subject	Μαλάρια
dc.subject	Malaria prophylaxis
dc.subject	Malaria chemoprophylaxis
dc.subject	Atovaquone - Proguanil
dc.subject	Tafenoquine
dc.subject	Mefloquinehe
dc.title	The efficacy of malaria chemoprofylaxis	en
heal.type	journalArticle
heal.generalDescription	Review article	en
heal.classification	Medicine
heal.classification	Ιατρική
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh00006614
heal.classificationURI	N/A-Ιατρική
heal.keywordURI	http://id.loc.gov/authorities/subjects/sh86003969
heal.keywordURI	http://lod.nal.usda.gov/34455
heal.language	en
heal.access	free
heal.recordProvider	Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας.Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Νοσηλευτικής	el
heal.publicationDate	2008-03
heal.bibliographicCitation	Saridi, M., Pappa, V. & Saroglou, G. (March 2008). The efficacy of malaria chemoprophylaxis. “Health Science Journal”. 2(1):3-14.	en
heal.abstract	Malaria is a highly contagious disease. According to W.H.O., its cases are expected to increase due to climate changes. Despite eradication efforts, malaria still remains one of the most significant causes of morbidity and mortality in tropical and subtropical regions. Many different antimalarial regimens are used; however resistance is emerging to many of them. Purpose: This critical review was conducted, in order to respond to the following questions. A) Which antimalarial regimen is the most effective? B) Which regimen is the safest for travelers in endemic regions? C) Which regimen is best tolerated? Methodology: The literature research was conducted through the Internet. The Medline and Cinahl databases were used, as well as the search engines google, altavista and lycos. The research included clinical trial articles. The studies were selected based on the aforementioned research questions and the chronological time limits. Results: Atovaquone/proguanil, tafenoquine, primaquine were the most effective regimens. Tafenoquine, as well as, primaquine were related to hemolytic incidents in individuals with G6PD deficiency, gastrointestinal disorders, backache and flu-like syndrome. Doxycycline and mefloquine were related to gastrointestinal and neurological disorders. Those were the less tolerated regimens. Conclusions: Atovaquone/proguanil, tafenoquine, primaquine were the most effective regimens. As far as safety is concerned, tafenoquine and primaquine should not be prescribed to individuals with G6PD deficiency. All the regimens were considered well tolerated, while most withdrawals due to adverse effects, took place in the doxycycline and mefloquine trials.	en
heal.publisher	Μαρβάκη, Χριστίνα	el
heal.journalName	Health Science Journal	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	true
heal.dateCreated	2008-01